Please login to the form below

Not currently logged in
Email:
Password:

Merck Serono

This page shows the latest Merck Serono news and features for those working in and with pharma, biotech and healthcare.

Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug

Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug

Prexton was set up in 2012 as a spin-out from Merck Serono’s R&D operations following the closure of its Geneva R&D centre.

Latest news

  • Merck and Pfizer set to win NICE backing for Bavencio Merck and Pfizer set to win NICE backing for Bavencio

    Merck and Pfizer set to win NICE backing for Bavencio. The PD-L1 inhibitor is being assessed for the treatment of mMCC patients. ... However Bavencio, which became the first checkpoint inhibitor cleared in Europe for mMCC patients, was developed by Merck

  • After Axovant shock, Roivant pens diabetes deal with Poxel After Axovant shock, Roivant pens diabetes deal with Poxel

    After Axovant shock, Roivant pens diabetes deal with Poxel. Acquires Merck Serono’s diabetes candidate imeglimin as part of the deal. ... by Merck Serono for type 2 diabetes, for $35m upfront and a $15m equity investment.

  • Novartis’ Extavia evades NICE restrictions on MS drugs Novartis’ Extavia evades NICE restrictions on MS drugs

    The appraisal rejected four other interferons - Biogen’s Avonex and long-acting variant Plegridy, Bayer’s Betaferon, and Merck Serono’s Rebif - as well as Teva’s non-interferon MS therapy

  • Merck, Pfizer cue up first EU launches for PD-L1 drug Bavencio Merck, Pfizer cue up first EU launches for PD-L1 drug Bavencio

    Merck KGaA and Pfizer's PD-L1 inhibitor Bavencio could be on the EU market from next month, after getting EMA approval as a treatment for the rare skin cancer Merkel ... The new product will be launched first in the UK and Germany, according to Merck,

  • The Owen Group launches healthcare agency The Owen Group launches healthcare agency

    The team behind the agency has already worked with global healthcare players on various projects, including building iPad applications for Novartis and Merck-Serono, a digital marketing store for Pfizer and

More from news
Approximately 23 fully matching, plus 169 partially matching documents found.

Latest Intelligence

  • A rare opportunity A rare opportunity

    The disappearance of that opportunity combined with changes at Merck following its 10.6bn acquisition of Serono gave Neil the momentum to set up his own consultancy business in 2007. ... He worked for a number of pharma clients, including Eisai and Merck

  • Sustainable solutions Sustainable solutions

    Over the summer Alex was appointed chair of the EMG, taking over from Merck' Serono's David Garmon-Jones, and he says both the EMG and its wider, UK industry counterpart ... In May 2014 it paid $14.2bn for Merck &Co's consumer health unit.

  • Deal Watch October 2015 Deal Watch October 2015

    This month's deal between Merck Serono (Merck KGaA) and BioMarin is a good example of this approach. ... Acquisition - company. 580. Merck Serono/ BioMarin. Kuvan and pegvaliase (Kuvan marketed; pegvaliase p3).

  • A bright future for OTC and Merck Consumer Health A bright future for OTC and Merck Consumer Health

    A bright future for OTC and Merck Consumer Health. It's an exciting time for the OTC sector. ... For Merck's Consumer Health business, change and growth in operations has also been driven by the incorporation of new brands, transferred from Merck Serono.

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    Phase 3 immuno-oncology treatment for prostate cancer. 975. Intrexon / Merck Serono.

More from intelligence
Approximately 1 fully matching, plus 18 partially matching documents found.

Latest appointments

More from appointments
Approximately 5 fully matching, plus 32 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

Established in 2002, Star is a full service outsourcing and resourcing company that works with the best people and opportunities...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics